<DOC>
	<DOCNO>NCT02468908</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , single ascending ( SAD ) , multiple ascend dose ( MAD ) study conduct single clinical site within UK . Healthy male female subject ( non-child bearing potential ) enrol investigate single inhale dos molgramostim 3 dose level ( Part 1 ) multiple inhaled dose 2 dose level ( Part 2 ) . The 2 dos multiple ascend dose regimen administer daily ( QD ) 6 consecutive day . The clinical indication inhale molgramostim treatment respiratory disease aPAP , bronchiectasis cystic fibrosis . The Clinical trial involve 42 healthy participant . The trial expect last approximately 4 month .</brief_summary>
	<brief_title>Inhaled Molgramostim ( rhGM-CSF ) Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Molgramostim</mesh_term>
	<criteria>1 . Healthy , adult , male female , 18 55 year age , inclusive , screen . 2 . Lifelong non smoker use nicotine containing product . 3 . Body mass index ( BMI ) ≥ 18.5 ≤ 32.0 kg/m2 screening . 4 . Medically healthy clinically significant medical history , physical examination , laboratory profile , spirometry , vital sign , ECGs , deem PI . 5 . Females must nonchild bear potential must undergo one follow sterilization procedure least 6 month prior dose Part 1 prior first dose Part 2 : hysteroscopic sterilization ; bilateral tubal ligation bilateral salpingectomy ; hysterectomy ; bilateral oophorectomy ; postmenopausal amenorrhea least 1 year prior dose Part 1 prior first dose Part 2 , FSH serum level consistent postmenopausal status per PI 's judgment . 6 . A non vasectomized , male subject must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study medication . ( No restriction require vasectomized male provide vasectomy perform 4 month prior study start . A male vasectomized less 4 month prior study start must follow restriction non vasectomized male ) . 7 . If male must agree donate sperm dose Part 1 first dose Part 2 , 90 day follow last dose . 8 . Understands study procedure inform consent form ( ICF ) , willing able comply protocol . 1 . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study . 2 . History presence clinically significant medical condition ( ) ( include ongoing active infection ) psychiatric condition ( ) disease ( ) opinion PI . 3 . History illness , opinion PI , might confound result study pose additional risk subject participation study . 4 . Abnormal spirometry test result , opinion PI . 5 . History severe unexplained adverse reaction aerosol delivery medicinal product . 6 . History presence alcoholism drug abuse within past 2 year prior screen . 7 . History presence hypersensitivity idiosyncratic reaction molgramostim relate compound ( i.e. , Growgen® , Leucomax® , Leukine® , Topleucon™ ) . 8 . Clinically significant history presence ECG abnormalities second third degree atrioventricular block , evidence , family history prolong QT syndrome . 9 . Allergy bandaids , adhesive dressing , medical tape . 10 . Positive urine drug screen check . 11 . Positive alcohol test checkin . 12 . Drink alcohol excess 21 unit per week male 14 unit per week female , one unit = 150 mL wine 360 mL beer 45 mL 45 % alcohol . 13 . Positive urine cotinine screen checkin . 14 . Positive result screen HIV , HBsAg , HCV . 15 . Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening . 16 . Seated heart rate lower 45 bpm high 99 bpm screening . 17 . QTcF interval &gt; 430 msec ( male ) &gt; 450 msec ( female ) screen deem clinically abnormal PI . 18 . Unable refrain anticipates use : Any drug , include prescription non prescription medication , herbal remedy , vitamin supplement begin 14 day prior dose Part 1 prior first dose Part 2 , throughout study . Hormone replacement therapy ( HRT ) permit study within 3 month prior screen . During study paracetamol ( 2 g per 24 hour ) may administer discretion PI . Any drug know significant inducer CYP enzymes and/or P gp , include St. John 's Wort , 28 day prior dose Part 1 prior first dose Part 2 , throughout study . Appropriate source consult PI designee confirm lack PK/PD interaction study drug . 19 . Have diet incompatible study diet , opinion PI , within 28 day prior first dose study drug , throughout study . 20 . Haemoglobin total WBC outside normal range screening . 21 . Donation blood plasma within 90 day prior dose Part 1 prior first dose Part 2 . 22 . Donation bone marrow within last 6 month prior dose Part 1 prior first dose Part 2 . 23 . Participation another clinical trial within 90 day prior dose Part 1 prior first dose Part 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>